• Explore /
  • Poster
  • / Nemvaleukin alfa combination therapy for gastrointestinal (GI) cancers: Preclinical evidence and clinical data from the ARTISTRY-1 trial.

Nemvaleukin alfa combination therapy for gastrointestinal (GI) cancers: Preclinical evidence and clinical data from the ARTISTRY-1 trial.

Abstract Video & Slides Poster

Authors

Ulka Vaishampayan

Ulka N. Vaishampayan

University of Michigan Cancer Center, Barbara Ann Karmanos Cancer Institute, Wayne State University (at time of study), Detroit, MI

Ulka N. Vaishampayan , Shipra Gandhi , Seth David Rosen , Anna Spreafico , Debora S. Bruno , Quincy S. Chu , Aman Chauhan , Olivier Dumas , Hal W. Hirte , Jared E. Lopes , Heather Losey , Yan Wang , Lei Sun , Monali Bhardwaj Desai , Rita P. Dalal , Yangchun Du , Julie R. Graham , Jameel Muzaffar , Ira Seth Winer

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2022 ASCO Gastrointestinal Cancers Symposium

Session Type

Poster Session

Session Title

Poster Session A: Cancers of the Esophagus and Stomach and Other GI Cancers

Track

Esophageal and Gastric Cancer,Other GI Cancer

Sub Track

Therapeutics

Clinical Trial Registration Number

NCT02799095

DOI

10.1200/JCO.2022.40.4_suppl.659

Abstract #

659

Poster Bd #

K3

Abstract Disclosures

Similar Posters

Poster

2022 ASCO Genitourinary Cancers Symposium

Nemvaleukin alfa in patients with advanced renal cell carcinoma: ARTISTRY-1.

Nemvaleukin alfa in patients with advanced renal cell carcinoma: ARTISTRY-1.

First Author: Emiliano Calvo

First Author: Sarina Anne Piha-Paul

First Author: Valentina Boni

First Author: Ulka N. Vaishampayan